首页 >>2014年06期
信号传导与转录激活因子3基因多态性与肝细胞癌的关系
作者:谢佳新 高秋菊 杨丹 刘天鹏 曹广文

摘要:

目的  探讨信号传导与转录激活因子3(signal transducer and activators of transcription 3, STAT3)基因启动子区–1096G/C多态性与乙肝表面抗原(HBsAg)阳性肝细胞癌(hepatocellular carcinoma, HCC)易感性之间的关系。方法  采用病例–对照研究方法,应用荧光探针实时定量PCR法对2009至2012年在上海某医院就诊的632例HCC患者和723名非HCC乙肝病毒(HBV)感染者的STAT3基因启动子区–1096G/C基因多态性进行检测,使用单因素分析方法确定该基因多态性OR(95%CI)值。结果  对照组、病例组携带STAT3 –1096C(GC+CC)基因型者分别占61.8%(447/723)、60.6%(383/632),不同基因型之间HCC发病风险差异无统计学意义(OR=0.95,95%CI:0.76~1.18)。以性别进行分层分析,在男性人群中,对照组、病例组携带STAT3 –1096 C(GC+CC)基因型者分别占62.2%(314/505)、61.8%(331/536),在女性人群中,分别为61.0%(133/218)、54.17%(52/96),在男性和女性人群中,不同基因型HCC发病风险差异均没有统计学意义(OR=0.98,95%CI:0.77~1.26;OR=0.76,95%CI:0.47~1.26)。以HBV基因型进行分层分析,在HBV B型感染者中,对照组、病例组携带STAT3 –1096C(GC+CC)基因型者分别占61.5%(110/179)、53.1%(34/64),在HBV C型感染者中,对照组、病例组携带STAT3 –1096C(GC+CC)基因型者分别占62.9%(276/439)、60.3%(226/375),在HBV B或C型感染者中,不同基因型患者HCC发病风险差异没有统计学意义(OR=0.71,95%CI:0.40~1.26;OR=0.90,95%CI:0.68~1.19)。结论  STAT3 –1096G/C基因多态性与HBV阳性HCC的易感性没有相关性。

关键词:癌,肝细胞;STAT3转录因子;病例对照研究;多态现象,遗传

Abstract:

Objective  To evaluate the association of signal transducer and activators of transcription 3 (STAT3) -1096G/C polymorphism in promoter region with the susceptibility to HBsAg positive hepatocellular carcinoma (HCC).Methods  A total of 632 patients with HCC and 723 HBV-infected subjects without HCC treated at Changhai Hospital of Shanghai from 2009 to 2012 were included in this case-control study. The polymorphism of STAT3 -1096 G/C was genotyped by Fluorescent probe-Real time quantitative PCR. Univariate analysis was used to calculate the odds ratio (OR) and its 95% confidence interval (CI).Results  The frequency of genetic allele STAT3 -1096G/C (GC+CC) of control group and case group were 61.83% (447/723) and 60.60% (383/632), while difference of HCC risk was not found among different genotypes (OR=0.95, 95%CI: 0.76-1.18). When stratified by sex, the frequency of genetic allele STAT3 -1096C (GC+CC) of control group and case group were 62.18% (314/505) and 61.75% (331/536) in men, 61.01% (133/218) and 54.17% (52/96) in women, respectively, while difference of HCC risk was not found among different genotypes (OR=0.98, 95%CI: 0.77-1.26; OR=0.76, 95%CI: 0.47-1.26, respectively). When stratified by HBV genotypes, the frequency of genetic allele STAT3 -1096C (GC+CC) of control group and case group were 61.45% (110/179) and 53.13% (34/64) in HBV genotype B, 62.87% (276/439) and 60.27% (226/375) in HBV genotype C, respectively, while difference of HCC risk was not found among different genotypes (OR=0.71, 95%CI: 0.40-1.26; OR=0.90, 95%CI: 0.68-1.19, respectively).Conclusion  STAT3 -1096G/C polymorphism was not associated with the susceptibility to HCC for the HBV-infected subjects without HCC.

Key words: Carcinoma,hepatocellular;STAT3 transcription factor;Case-control study;Polymorphism,genetic

发表日期:2014/6

引用本文:

图/表:

  • 10.3760/cma.j.issn.0253-9624.2014.06.018.T001:表1 两组研究对象一般情况比较

    10.3760/cma.j.issn.0253-9624.2014.06.018.T001:表1 两组研究对象一般情况比较

  • 10.3760/cma.j.issn.0253-9624.2014.06.018.F001:图1 rs17884075基因型检测散点分布图

    10.3760/cma.j.issn.0253-9624.2014.06.018.F001:图1 rs17884075基因型检测散点分布图

  • 10.3760/cma.j.issn.0253-9624.2014.06.018.T002:表2 STAT3 –1096 G/C基因型分布及与HCC的患病关系

    10.3760/cma.j.issn.0253-9624.2014.06.018.T002:表2 STAT3 –1096 G/C基因型分布及与HCC的患病关系

  • 10.3760/cma.j.issn.0253-9624.2014.06.018.T003:表3 STAT3 –1096 G/C在不同性别人群的分布及与HCC的患病关系

    10.3760/cma.j.issn.0253-9624.2014.06.018.T003:表3 STAT3 –1096 G/C在不同性别人群的分布及与HCC的患病关系

  • 10.3760/cma.j.issn.0253-9624.2014.06.018.T004:表4 STAT3 –1096 G/C在不同HBV基因型分布及与HCC的患病关系

    10.3760/cma.j.issn.0253-9624.2014.06.018.T004:表4 STAT3 –1096 G/C在不同HBV基因型分布及与HCC的患病关系

参考文献:

[1]ChenM, TherneauT, OrsiniLS, et al. Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma[J]. BMC Gastroenterol, 2011, 11:53.
[2]WeiRC, CaoX, GuiJH, et al. Augmenting the antitumor effect of TRAIL by SOCS3 with double–regulated replicating oncolytic adenovirus in hepatocellular carcinoma[J]. Hum Gene Ther, 2011, 22(9):1109–1119.
[3]张虹, 王敏, 刘伟, 等. 肝癌细胞中STAT3及c–myc的表达及其意义[J]. 肿瘤, 2008, 28(5):394–397.
[4]WangXH, MengXW, XingH, et al. STAT3 and beta–catenin signaling pathway may affect GSK–3 beta expression in hepatocellular carcinoma[J]. Hepatogastroenterology, 2011, 58(106):487–491.
[5]ChenJ, YinJ, TanX, et al. Improved multiplex–PCR to identify hepatitis B virus genotypes A–F and subgenotypes B1, B2, C1 and C2[J]. J Clin Virol, 2007, 38(3):238–243.
[6]XieJ, ZhangY, ZhangQ, et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma[J]. Hepatology, 2013, 57(6):2369–2377.
[7]谢佳新, 殷建华, 张琪, 等. JAK/STAT信号通路中关键分子基因多态性与肝细胞癌易感性的关系[J]. 中华流行病学杂志, 2012, 33(2):87–91.
[8]ChanHL, TseCH, MoF, et al. High viral load and hepatitis B virus subgenotypes are associated with increased risk of hepatocellular carcinoma[J]. J Clin Oncol, 2008, 26(2):177–182.
[9]YuMW, YehSH, ChenPJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men[J]. J Natl Cancer Inst, 2005, 97(4):265–272.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号